reports
Pfizer to Showcase Scientific Advancements in Respiratory and Other In...
NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024. Data in 49 abstracts from company- and collaborator-led studies, will highlight the advances Pfizer is making in helping prevent and treat infectious diseases. “Pfizer is at the forefront of vaccine and therapeutic development in respiratory and infectious diseases,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer. “IDWeek 2024 provides a crucial platform t...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events ...
- Dave Nicoski
- Ross LaDuke
ULTA ULTA BEAUTY INC
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MLAB MESA LABORATORIES INC.
KRC KILROY REALTY CORPORATION
HAIN HAIN CELESTIAL GROUP INC.
GDOT GREEN DOT CORPORATION CLASS A
FIVE FIVE BELOW INC.
EXPE EXPEDIA GROUP INC.
EGBN EAGLE BANCORP INC.
CF CF INDUSTRIES HOLDINGS INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BRKL BROOKLINE BANCORP INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
ALGN ALIGN TECHNOLOGY INC.
WY WEYERHAEUSER COMPANY
DRI DARDEN RESTAURANTS INC.
FMC FMC CORPORATION
THS TREEHOUSE FOODS INC.
TR TOOTSIE ROLL INDUSTRIES INC.
VFC V.F. CORPORATION
ASIX ADVANSIX INC.
PFE PFIZER INC.
CSCO CISCO SYSTEMS INC.
CTVA CORTEVA INC
CPRI CAPRI HOLDINGS LIMITED
GL GLOBE LIFE INC.
ASO ACADEMY SPORTS AND OUTDOORS
CZR CAESARS ENTERTAINMENT INC
CHK CHESAPEAKE ENERGY CORP
NYMT NEW YORK MORTGAGE TRUST INC.
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-ada...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- (NYSE: PFE, “Pfizer”) and (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission will review the CHMP’s recommendation and is expected to make a final decision soon. Following the EC decision, Pfizer and Bi...
Pfizer Invites Public to View and Listen to Webcast of October 29 Conf...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, October 29, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. Participants are advised to ...
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Pat...
NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting condition that can significantly impact quality of life in affected patients with cancer.ii,iii Results will be presented today as a late-breaking Proffered Paper Presentation (LBA82) at the European Society for Medical Oncology (ESMO...
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Re...
NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). After an additional 18 months of follow-up, the objective response rate (ORR) and the median duration of response (DoR) as assessed by independent radiology review were 75% and 40 months in treatment-naïve patients and 46% and 16.7 months in previously treated patients, resp...
Pfizer Highlights Diverse Oncology Portfolio and Combination Approache...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17 in Barcelona. Data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts, including more than 10 oral and mini-oral presentations, will be presented across the company’s tumor areas and core scientific modalities, as well as a potential treatment for a cancer-related condition. “At ...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussi...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 8:30 a.m. EDT. To view and listen to the webcast, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. The transcript and webcast replay of the discussion will be made available on our web site at within 24 hours after ...
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today introduced , a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S. The new, end-to-end experience will support the millions of Americans affected annually by common illnesses like migraine, COVID-19 or flu, and those seeking to protect themselves with adult vaccinations. By bringing together critical resources and services into a single destination, PfizerForAll helps individuals and their families cut down on the time and steps needed to take imp...
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omic...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- (NYSE: PFE, “Pfizer”) and (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies’ Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine. This season’s vaccine is for use as a single dose for most individuals 5 years of age and olde...
- Dave Nicoski
- Ross LaDuke
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine P...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- (NYSE: PFE, “Pfizer”) and (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate consists of Pfizer’s mRNA-based influenza vaccine candidate with the companies’ licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity objectives (immunogenicity against SARS-CoV-2 as well as immunogenicity against influenza A and B), of which one ...
Pfizer Inc: 1 director
A director at Pfizer Inc sold 5,154 shares at 28.660USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocomprom...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial () MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness), evaluating two doses of ABRYSVO vaccine in immunocompromised adults aged 18 and older at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD). Adults with immunocompromising conditions have an increased risk of developing RSV-LRTD. Substudy B of the MONeT trial was conducted to a...
- Dave Nicoski
- Ross LaDuke
XEL XCEL ENERGY INC.
SGRY SURGERY PARTNERS INC.
SGMO SANGAMO THERAPEUTICS INC.
PLOW DOUGLAS DYNAMICS INC.
NWL NEWELL BRANDS INC
MCD MCDONALD'S CORPORATION
LAD LITHIA MOTORS INC. CLASS A
HAS HASBRO INC.
GTY GETTY REALTY CORP.
CLX CLOROX COMPANY
APD AIR PRODUCTS AND CHEMICALS INC.
ANGO ANGIODYNAMICS INC.
ALKS ALKERMES PLC
LBRDA LIBERTY BROADBAND CORP. CLASS A
MAT MATTEL INC.
UHT UNIVERSAL HEALTH REALTY INCOME TRUST
VFC V.F. CORPORATION
FLGT FULGENT GENETICS
PFE PFIZER INC.
CWEN CLEARWAY ENERGY INC. CLASS C
PEAK HEALTHPEAK PROPERTIES INC.
LSTR ELECTROSTAR S.A.
MTCH MATCH GROUP INC.
HRMY HARMONY BIOSCIENCES HOLDINGS
BALY BALLYS CORPORATION
SHYF THE SHYFT GROUP INC
NWM NORWEST MINERALS
DOUG DOUGLAS ELLIMAN INC
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guid...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2024 and raised its full-year 2024 guidance(1) for both Revenues and Adjusted(2) diluted EPS. The second-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at . EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We are driving progress toward our 2024 strategic priorities through solid execution across the company. I am pleased with the strong per...
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparv...
NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74. DURVEQTIX is designed to enable people living with hemophilia B to produce factor IX (FIX) themselves via a one-time dose, rather than multiple intravenous FIX infusions weekly or bi...
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemoph...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study () evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A. The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment. Following a single 3e13 vg/kg dose, giroctocogene...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.